Therapeutic advances in alcohol-associated hepatitis

In recent years, there have been important advances in our understanding of alcohol-associated hepatitis (AH), which have occurred in parallel with a surge in clinical trial activity. Meanwhile, the broader medical field has seen a transformation in care paradigms based on emerging digital technologies. This review focuses on breakthroughs in our understanding of AH and how these breakthroughs are leading to new paradigms for biomarker discovery, clinical trial activity, and care models for patients. It portends a future in which multimodal data from genetic, radiomic, histologic, and environmental sources can be integrated and synthesised to generate personalised biomarkers and therapies for patients with AH. (C) 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Automated summary

In recent years, there has been significant progress in understanding alcohol-associated hepatitis (AH), accompanied by an increase in clinical trial activity. This review focuses on breakthroughs in AH understanding, which are leading to new paradigms for biomarker discovery, clinical trial activity, and patient care models. It suggests a future where multimodal data can be integrated to generate personalized biomarkers and therapies for patients with AH.